Wolfgang Wick
#102,636
Most Influential Person Now
Researcher
Wolfgang Wick's AcademicInfluence.com Rankings
Wolfgang Wickcomputer-science Degrees
Computer Science
#3678
World Rank
#3866
Historical Rank
Algorithms
#103
World Rank
#103
Historical Rank
Machine Learning
#502
World Rank
#508
Historical Rank
Database
#986
World Rank
#1038
Historical Rank
Wolfgang Wickbiology Degrees
Biology
#5224
World Rank
#7653
Historical Rank
Bioinformatics
#52
World Rank
#53
Historical Rank
Computational Biology
#74
World Rank
#74
Historical Rank
Download Badge
Computer Science Biology
Why Is Wolfgang Wick Influential?
(Suggest an Edit or Addition)Wolfgang Wick's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010) (2448)
- Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. (2014) (1957)
- Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (2012) (1532)
- DNA methylation-based classification of central nervous system tumours (2018) (1461)
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) (1423)
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas (2009) (1062)
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. (2012) (925)
- NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. (2009) (779)
- Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. (2008) (747)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) (744)
- Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo (2002) (742)
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) (736)
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010) (714)
- Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. (2008) (682)
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010) (667)
- Brain tumour cells interconnect to a functional and resistant network (2015) (655)
- Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma (2017) (650)
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014) (601)
- Standards of care for treatment of recurrent glioblastoma--are we there yet? (2013) (582)
- A vaccine targeting mutant IDH1 induces antitumour immunity (2014) (576)
- Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. (2012) (542)
- Lomustine and Bevacizumab in Progressive Glioblastoma (2017) (540)
- Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. (2015) (522)
- Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (518)
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) (486)
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. (2015) (486)
- Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. (2001) (481)
- Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. (2010) (460)
- Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force (2010) (453)
- Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine (2007) (452)
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. (2017) (452)
- DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. (2017) (447)
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015) (438)
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. (2015) (436)
- Glutamatergic synaptic input to glioma cells drives brain tumour progression (2019) (432)
- SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo (2004) (416)
- MGMT testing—the challenges for biomarker-based glioma treatment (2014) (413)
- Brain Tumor Segmentation and Radiomics Survival Prediction: Contribution to the BRATS 2017 Challenge (2017) (411)
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
- ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma (2014) (367)
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (2016) (342)
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma (2008) (325)
- No New-Net (2018) (313)
- Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. (2016) (308)
- RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo (2004) (303)
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis (2013) (298)
- Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R (2009) (290)
- O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells (2006) (290)
- Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors (2015) (287)
- Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt (2002) (287)
- Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial (2019) (275)
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (2017) (271)
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (264)
- Glioma Cell Invasion: Regulation of Metalloproteinase Activity by TGF-β (2001) (260)
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial (2015) (256)
- Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system (2013) (254)
- Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. (2007) (252)
- cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant (2018) (251)
- Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups (2015) (245)
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. (2015) (244)
- Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma (2014) (243)
- IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma (2015) (243)
- IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO (2015) (241)
- Novel, improved grading system(s) for IDH-mutant astrocytic gliomas (2018) (236)
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderly (2012) (234)
- Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience (2018) (232)
- Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. (2001) (232)
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (2015) (230)
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR (2014) (227)
- Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. (2016) (221)
- Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response (2016) (216)
- Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. (2019) (216)
- Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation (2013) (204)
- Glioma (2015) (202)
- Automated brain extraction of multisequence MRI using artificial neural networks (2019) (197)
- High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images: Evaluation of the Macrocyclic Gadolinium-Based Contrast Agent Gadobutrol (2015) (190)
- Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. (2012) (189)
- Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets (2016) (188)
- Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. (2015) (183)
- Molecular neuro-oncology in clinical practice: a new horizon. (2013) (182)
- Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma (2014) (180)
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. (2016) (173)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (171)
- Brain metastases: pathobiology and emerging targeted therapies (2012) (168)
- Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors (2000) (166)
- Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. (2015) (166)
- One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma (2004) (162)
- How to use and assess qualitative research methods (2020) (162)
- Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. (2002) (160)
- Therapeutic options in recurrent glioblastoma--An update. (2016) (159)
- Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration (2015) (159)
- New (alternative) temozolomide regimens for the treatment of glioma. (2009) (157)
- Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas (2017) (155)
- Pathway inhibition: emerging molecular targets for treating glioblastoma. (2011) (155)
- Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma (2018) (154)
- Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations (2018) (154)
- Molecular diagnostics of gliomas: the clinical perspective (2010) (153)
- Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. (2006) (151)
- Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma (2018) (149)
- Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. (1999) (147)
- Sarcoma classification by DNA methylation profiling (2021) (147)
- Relaxation-compensated CEST-MRI of the human brain at 7T: Unbiased insight into NOE and amide signal changes in human glioblastoma (2015) (146)
- Glioblastoma (2006) (144)
- Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma (2013) (144)
- Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. (2000) (144)
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy (2013) (141)
- Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. (2006) (138)
- Transforming growth factor-β and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth (1999) (138)
- A vaccine targeting mutant IDH1 in newly diagnosed glioma (2021) (137)
- Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo (2017) (135)
- Molecular determinants of glioma cell migration and invasion. (2001) (135)
- Optimal management of elderly patients with glioblastoma. (2013) (132)
- Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. (2016) (131)
- The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells (2011) (129)
- cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) (2018) (127)
- GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas (2010) (127)
- PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis (1999) (126)
- Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. (2009) (125)
- Epilepsy meets cancer: when, why, and what to do about it? (2012) (124)
- Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. (2014) (124)
- Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma (2012) (123)
- Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. (1996) (122)
- The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. (2013) (122)
- Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells (2012) (121)
- Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects (2014) (120)
- Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. (2014) (119)
- Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling (2014) (117)
- Clinical trial end points for high-grade glioma: the evolving landscape. (2011) (117)
- Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-β-dependent HIF-1α-mediated induction of CXCL12 (2006) (116)
- Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo (2005) (116)
- Vaccine-based immunotherapeutic approaches to gliomas and beyond (2017) (116)
- EANO Guideline on the Diagnosis and Treatment of Vestibular Schwannoma. (2019) (115)
- Bevacizumab and recurrent malignant gliomas: a European perspective. (2010) (115)
- Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (2016) (109)
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials (2013) (108)
- Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. (2002) (107)
- Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy: A Systematic Review and Meta-analysis. (2019) (107)
- Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins (2003) (107)
- A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma (2014) (106)
- The Potential of Relaxation-Weighted Sodium Magnetic Resonance Imaging as Demonstrated on Brain Tumors (2011) (105)
- Rechallenge with temozolomide in patients with recurrent gliomas (2009) (104)
- Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? (2011) (103)
- Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma (2011) (101)
- Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness (2011) (101)
- Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. (2015) (101)
- Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma (2016) (100)
- Downfield‐NOE‐suppressed amide‐CEST‐MRI at 7 Tesla provides a unique contrast in human glioblastoma (2017) (100)
- Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology (2017) (99)
- Treatment of glioblastoma in adults (2018) (98)
- Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells (2009) (98)
- Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2 (2001) (97)
- Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma (2014) (97)
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) (2016) (97)
- Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence (2018) (94)
- Bevacizumab for newly diagnosed glioblastoma. (2014) (94)
- Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases (2016) (93)
- Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas (2020) (92)
- Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. (2007) (92)
- LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL (2015) (91)
- Tryptophan degradation in autoimmune diseases (2007) (91)
- Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. (2007) (90)
- Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. (2009) (90)
- Tweety-Homolog 1 Drives Brain Colonization of Gliomas (2017) (90)
- No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents. (2017) (88)
- Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial (2010) (88)
- Emerging intersections between neuroscience and glioma biology (2019) (88)
- A novel tool to analyze MRI recurrence patterns in glioblastoma. (2008) (87)
- Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. (2005) (87)
- Steroids in neurooncology: actions, indications, side-effects. (2010) (86)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (85)
- Bevacizumab does not increase the risk of remote relapse in malignant glioma (2011) (85)
- N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) inhibits transforming growth factor‐β release and reduces migration and invasiveness of human malignant glioma cells (2001) (85)
- Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. (2015) (85)
- Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. (2013) (85)
- Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T (2018) (85)
- Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents (2016) (83)
- Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. (2015) (83)
- Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. (2012) (83)
- Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma (2013) (80)
- Synergistic antiglioma activity of radiotherapy and enzastaurin (2007) (80)
- Pediatric Brain: No Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-weighted MR Images after Consecutive Exposure to a Macrocyclic Gadolinium-based Contrast Agent. (2017) (80)
- Gliomatosis cerebri: Molecular pathology and clinical course (2002) (80)
- N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. (2018) (79)
- A malignant cellular network in gliomas: potential clinical implications. (2016) (78)
- Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial (2010) (78)
- Pharmacotherapy of Epileptic Seizures in Glioma Patients: Who, When, Why and How Long? (2005) (78)
- Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation (2014) (78)
- Diagnostic challenges in meningioma. (2017) (77)
- Individualized Targeted Therapy for Glioblastoma: Fact or Fiction? (2012) (77)
- Surviving glioblastoma for more than 5 years: The patient's perspective (2006) (77)
- CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas (2020) (77)
- Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. (2020) (76)
- In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis (2016) (76)
- Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. (2014) (75)
- Brain Edema in Neurooncology: Radiological Assessment and Management (2004) (73)
- Nuclear Overhauser Enhancement Mediated Chemical Exchange Saturation Transfer Imaging at 7 Tesla in Glioblastoma Patients (2014) (73)
- Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. (2016) (71)
- Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 (2006) (69)
- Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series (2021) (68)
- Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas (2021) (67)
- Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. (2006) (67)
- K27M-mutant histone-3 as a novel target for glioma immunotherapy (2017) (67)
- Neurological sequelae of cancer immunotherapies and targeted therapies. (2016) (67)
- Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence (2011) (66)
- Glioblastoma hijacks neuronal mechanisms for brain invasion (2022) (65)
- Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?: A Feasibility Study. (2019) (64)
- The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 (2018) (64)
- T1ρ-weighted Dynamic Glucose-enhanced MR Imaging in the Human Brain. (2017) (64)
- EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. (2016) (63)
- Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. (2005) (62)
- Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. (2010) (62)
- Chemotherapy‐induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity (2004) (62)
- cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification (2017) (62)
- Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome (2016) (61)
- Current status and future directions of anti-angiogenic therapy for gliomas. (2016) (61)
- No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas (2012) (61)
- Association of overall survival in patients with newly diagnosed glioblastoma with contrast‐enhanced perfusion MRI: Comparison of intraindividually matched T1‐ and T2*‐based bolus techniques (2015) (59)
- Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas (2020) (59)
- Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression (2016) (59)
- Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging. (2013) (57)
- Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma (2020) (57)
- Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. (2013) (55)
- A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. (2020) (55)
- Integrated molecular characterization of IDH‐mutant glioblastomas (2018) (55)
- S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
- Association of Blood Pressure With Short- and Long-Term Functional Outcome After Stroke Thrombectomy: Post Hoc Analysis of the SIESTA Trial (2018) (55)
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. (2021) (55)
- TTFields: where does all the skepticism come from? (2016) (55)
- Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. (2019) (55)
- Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression (2014) (54)
- Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). (2010) (54)
- Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial (2010) (53)
- Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas (2011) (53)
- A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). (2016) (53)
- Adjuvant therapy. (2020) (53)
- Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function (2007) (53)
- Outcome and prognostic factors of radiation therapy for medulloblastoma. (2011) (52)
- Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology (2019) (52)
- P‐Glycoprotein and Multidrug Resistance‐associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells (2003) (52)
- Mutational patterns and regulatory networks in epigenetic subgroups of meningioma (2019) (52)
- Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma (2018) (51)
- Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography (2017) (51)
- Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
- NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). (2010) (50)
- ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA (2016) (50)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. (2013) (50)
- BCL‐2‐induced glioma cell invasiveness depends on furin‐like proteases (2004) (50)
- Molecular predictors of outcome in low-grade glioma. (2012) (49)
- Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) (2018) (49)
- KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. (2012) (49)
- ACNU-based chemotherapy for recurrent glioma in the temozolomide era (2008) (48)
- Pirfenidone inhibits TGF-β expression in malignant glioma cells (2007) (48)
- Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients (2018) (48)
- MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma. (2016) (48)
- Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. (2012) (47)
- NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP (2015) (47)
- The mTOR signaling pathway as a treatment target for intracranial neoplasms. (2015) (47)
- Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials (2011) (47)
- How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. (2005) (47)
- Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. (2016) (47)
- Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma (2017) (47)
- Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. (2009) (46)
- Modulation of TGF‐β activity by latent TGF‐β‐binding protein 1 in human malignant glioma cells (2009) (46)
- Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). (2013) (46)
- Suppression of TDO‐mediated tryptophan catabolism in glioblastoma cells by a steroid‐responsive FKBP52‐dependent pathway (2015) (46)
- APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. (2011) (46)
- Modulation of MDR/MRP by wild-type and mutant p53. (2001) (46)
- BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells (2006) (45)
- Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 (2019) (45)
- Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma (2015) (45)
- Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase (2012) (44)
- Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients (2019) (44)
- Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation (2018) (44)
- Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol (2016) (44)
- Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. (2019) (44)
- Microenvironmental Clues for Glioma Immunotherapy (2014) (43)
- Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. (2016) (42)
- A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). (2016) (42)
- Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. (2001) (42)
- Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps (2017) (42)
- Concepts in glioma immunotherapy (2016) (42)
- Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. (2019) (41)
- Proximity ligation assay evaluates IDH1R132H presentation in gliomas. (2015) (40)
- The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas (2016) (40)
- Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica? (2010) (40)
- DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development (2019) (40)
- Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? (2014) (40)
- Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis (2013) (40)
- Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab (2014) (39)
- Adenoviral natural born killer gene therapy for malignant glioma. (2003) (38)
- No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after more than 20 Serial Injections of Macrocyclic Gadolinium-Based Contrast Agents (2017) (38)
- Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment (2013) (38)
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2018) (38)
- Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis (2017) (38)
- Tryptophan‐2,3‐dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor‐4 (2016) (38)
- Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (2013) (37)
- Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. (2016) (37)
- Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. (2020) (36)
- Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology (2015) (36)
- Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. (2016) (36)
- Temozolomide: a milestone in the pharmacotherapy of brain tumors. (2005) (35)
- Neoadjuvant Gemcitabine/treosulfan Chemotherapy for Newly Diagnosed Glioblastoma (2004) (35)
- Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions (2019) (35)
- YAP1-fusions in pediatric NF2-wildtype meningioma (2019) (35)
- Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (2013) (34)
- PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. (2017) (34)
- Harmful networks in the brain and beyond (2018) (34)
- Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study (2008) (34)
- Pirfenidone inhibits TGF-beta expression in malignant glioma cells. (2007) (34)
- Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma (2017) (33)
- Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 (2019) (33)
- Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib (2018) (33)
- Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis (2015) (32)
- Infratentorial IDH-mutant astrocytoma is a distinct subtype (2020) (32)
- Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice (2007) (32)
- Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA (2019) (31)
- CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. (2020) (31)
- Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. (2016) (31)
- Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma (2015) (30)
- Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma (2018) (30)
- Cerebrospinal fluid proteomic profiling in nusinersen‐treated patients with spinal muscular atrophy (2020) (30)
- Glioblastoma in elderly patients: solid conclusions built on shifting sand? (2018) (30)
- Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis (2020) (30)
- Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry (2018) (30)
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (30)
- Anti-Angiogenics: Their Role in the Treatment of Glioblastoma (2018) (29)
- Quantification of Tumor Vessels in Glioblastoma Patients Using Time-of-Flight Angiography at 7 Tesla: A Feasibility Study (2014) (29)
- A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network (2013) (29)
- Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. (2011) (29)
- Mechanisms of Resistance of Human Glioma Cells to Apo2 Ligand/TNF-Related Apoptosis-Inducing Ligand (2006) (29)
- SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. (2021) (28)
- Synaptic Input to Brain Tumors: Clinical Implications. (2020) (28)
- Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives (2010) (28)
- Enzastaurin‐induced apoptosis in glioma cells is caspase‐dependent and inhibited by BCL‐XL (2008) (28)
- Neuronal signatures in cancer (2020) (28)
- Systematic review of combinations of targeted or immunotherapy in advanced solid tumors (2021) (27)
- Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study (2018) (27)
- CMV infection and glioma, a highly controversial concept struggling in the clinical arena. (2014) (27)
- Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? (2015) (27)
- Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms (2014) (27)
- Phase 0 and Window of Opportunity Clinical Trial Design in Neuro-Oncology: A RANO Review. (2020) (27)
- Understanding and targeting alkylator resistance in glioblastoma. (2014) (27)
- Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma (2011) (27)
- Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? (2019) (27)
- Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM) (2020) (26)
- De novo erythropoietin receptor (EPO‐R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival (2007) (26)
- Quantitative Dynamic Oxygen 17 MRI at 7.0 T for the Cerebral Oxygen Metabolism in Glioma. (2020) (26)
- Deep Probabilistic Modeling of Glioma Growth (2019) (26)
- Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy (2018) (26)
- Federated learning enables big data for rare cancer boundary detection (2022) (26)
- The aryl hydrocarbon receptor in tumor immunity (2012) (26)
- PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion (2019) (26)
- Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. (2020) (26)
- Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors (2021) (25)
- Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting (2016) (25)
- Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy (2016) (25)
- Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas (2012) (25)
- Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? (2010) (25)
- Shaping the glioma immune microenvironment through tryptophan metabolism. (2012) (24)
- Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio (2018) (24)
- Brain Tumor Segmentation Using Large Receptive Field Deep Convolutional Neural Networks (2017) (24)
- Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine (2017) (23)
- Neuroradiological Response Criteria for High-grade Gliomas (2011) (23)
- Mutant IDH1: An immunotherapeutic target in tumors (2014) (23)
- CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III Randomized Study of RT vs. RT+TMZ vs. TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodendroglial Tumors. Analysis of Patients Treated on the Original Protocol Design (PL02.005) (2016) (23)
- Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. (2012) (23)
- Expression and functional activity of osteoprotegerin in human malignant gliomas (2003) (23)
- N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon‐γ (IFN‐γ) (2001) (22)
- Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. (2020) (22)
- Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors (2021) (22)
- T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology (2020) (22)
- VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. (2008) (22)
- Suppression of Th1 differentiation by tryptophan supplementation in vivo (2017) (22)
- Supraagonistic, bispecific single‐chain antibody purified from the serum of cloned, transgenic cows induces T‐cell‐mediated killing of glioblastoma cells in vitro and in vivo (2005) (22)
- Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept (2010) (21)
- Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma (2016) (21)
- German Cancer Consortium (DKTK) – A national consortium for translational cancer research (2019) (21)
- Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations (2021) (21)
- Geriatric neuro-oncology: from mythology to biology. (2011) (21)
- Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ (2020) (21)
- Chemotherapy for intracranial ependymoma in adults (2016) (21)
- Cortical vessel sign on susceptibility weighted imaging reveals clinically relevant hypoperfusion in internal carotid artery stenosis. (2016) (21)
- Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? (2011) (21)
- Glioblastoma in the elderly: making sense of the evidence. (2016) (20)
- The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. (2019) (20)
- Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. (1999) (20)
- Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1 (2020) (20)
- Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model. (2020) (20)
- Anticoagulation for radiation-induced neurotoxicity revisited (2008) (20)
- The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. (2021) (20)
- Neuro-oncology in 2013: Improving outcome in newly diagnosed malignant glioma (2014) (20)
- ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS (2018) (20)
- Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma (2018) (20)
- NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment. (2016) (19)
- Defective p53 antiangiogenic signaling in glioblastoma. (2010) (19)
- Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. (2019) (19)
- Virtual Raters for Reproducible and Objective Assessments in Radiology (2016) (19)
- Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). (2014) (19)
- Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trials. (2014) (19)
- NDRG1 prognosticates the natural course of disease in WHO grade II glioma (2014) (18)
- Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. (2015) (18)
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma (2019) (18)
- Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome (2010) (18)
- Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI (2018) (18)
- Regulation of pulmonary Pseudomonas aeruginosa infection by the transcriptional repressor Gfi1 (2006) (18)
- Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies (2013) (18)
- Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). (2011) (18)
- Current usage of tumor treating fields for glioblastoma (2020) (18)
- Tumor cell network integration in glioma represents a stemness feature. (2020) (17)
- Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis. (2014) (17)
- Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients (2017) (17)
- Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma (2019) (17)
- Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2019) (17)
- Treatment of anaplastic glioma. (2015) (17)
- Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. (2021) (17)
- General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation (2016) (17)
- Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs (2020) (17)
- Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021) (17)
- Understanding and Treating Glioblastoma. (2018) (17)
- Prognostic relevance of miRNA-155 methylation in anaplastic glioma (2016) (17)
- Chemical exchange saturation transfer (CEST) signal intensity at 7T MRI of WHO IV° gliomas is dependent on the anatomic location (2018) (17)
- Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter. (2014) (17)
- Glioma tropism of lentivirally transduced hematopoietic progenitor cells. (2010) (16)
- Classification and management of anaplastic gliomas (2009) (16)
- Sequential proton boost after standard chemoradiation for high-grade glioma. (2017) (16)
- Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia (2007) (16)
- Disconnecting multicellular networks in brain tumours (2022) (16)
- Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy (2019) (16)
- Advances in malignant glioma drug discovery (2011) (16)
- ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN. (2015) (16)
- Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo (2018) (15)
- Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas (2018) (15)
- Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1 (2021) (15)
- Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma (2018) (15)
- Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. (2019) (15)
- Capillary Transit Time Heterogeneity Is Associated with Modified Rankin Scale Score at Discharge in Patients with Bilateral High Grade Internal Carotid Artery Stenosis (2016) (15)
- Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. (2020) (14)
- RTOG 9802: good wines need aging. (2013) (14)
- Differential Expression of Egr1 and Activation of Microglia Following Irradiation in the Rat Brain (2007) (14)
- Phase III Trial of Bevacizumab Added to Standard Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Final Progression-Free Survival and Preliminary Overall Survival Results from AVAglio (PL02.002) (2013) (14)
- Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. (2016) (14)
- Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. (2020) (14)
- Intracranial Metastatic Esthesioneuroblastoma Responsive to Temozolomide (2004) (14)
- Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells (2020) (14)
- Tunneling nanotube‐like structures in brain tumors (2019) (14)
- Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease (2019) (13)
- N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). (2001) (13)
- Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells (2009) (13)
- Challenging cytomegalovirus data in glioblastoma. (2014) (13)
- Determining medical decision-making capacity in brain tumor patients: why and how? (2020) (13)
- First results on the DCVax phase III trial: raising more questions than providing answers. (2018) (13)
- TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. (2020) (13)
- Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases (2020) (12)
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2019) (12)
- Good maths is needed to understand CMV data in glioblastoma (2014) (12)
- A PRDX1‐p38α heterodimer amplifies MET‐driven invasion of IDH‐wildtype and IDH‐mutant gliomas (2018) (12)
- GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. (2018) (12)
- Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM). (2013) (12)
- Oligosarcomas, IDH-mutant are distinct and aggressive (2021) (12)
- Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study (2020) (12)
- No preferential loss of paternal 19q alleles in oligodendroglial tumors (2003) (12)
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2021) (11)
- Treosulfan Chemotherapy for Recurrent Malignant Glioma (2000) (11)
- APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. (2012) (11)
- Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial (2021) (11)
- Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression. (2013) (11)
- A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. (2021) (11)
- Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. (2013) (11)
- Outcome of patients with proximal vessel occlusion of the anterior circulation and DWI-PWI mismatch is time-dependent. (2017) (11)
- Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)—Eudract number 2005–003911–63; NCT00311857 (2008) (11)
- Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05) (2011) (11)
- LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance (2020) (11)
- Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. (2017) (11)
- Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas (2016) (11)
- The mTOR target NDRG 1 confers MGMT-dependent resistance to alkylating chemotherapy (2017) (11)
- Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial (2021) (11)
- Vaccine Strategies in Gliomas (2018) (11)
- AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. (2011) (11)
- The KEEP SIMPLEST Study: Improving In-House Delays and Periinterventional Management in Stroke Thrombectomy—A Matched Pair Analysis (2019) (11)
- New glioblastoma heterogeneity atlas — a shared resource (2018) (11)
- Human Cancer Biology Costimulatory Protein 4 IgB 7 H 3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness (2011) (10)
- Examining cognitive emotion regulation in frontal lobe patients: The mediating role of response inhibition. (2015) (10)
- Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis (2020) (10)
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2018) (10)
- Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes (2020) (10)
- Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy? (2010) (10)
- Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. (2018) (10)
- cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma (2019) (10)
- Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients (2020) (10)
- Emerging targets for anticancer vaccination: IDH (2021) (10)
- Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage? (2021) (10)
- Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma (2014) (10)
- Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee (2020) (10)
- Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma. (2010) (10)
- Adult precision medicine: learning from the past to enhance the future (2020) (10)
- Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score Using Hypointense Vessels on Susceptibility Weighted Imaging Independently Predicts Outcome in Patients with Basilar Artery Occlusion (2015) (9)
- Malignant astrocytoma in elderly patients: where do we stand? (2013) (9)
- MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. (2014) (9)
- Susceptibility‐weighted imaging in malignant melanoma brain metastasis (2019) (9)
- Astrocytic gliomas WHO grades II and III. (2016) (9)
- Autonomous rhythmic activity in glioma networks drives brain tumour growth (2022) (9)
- L-dopa-resistant parkinsonism syndrome following cerebral radiation therapy for neoplasm. (2000) (9)
- Dysfunctional dendritic cells limit antigen-specific T cell response in glioma (2022) (9)
- INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. (2020) (9)
- Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma (2019) (9)
- Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? (2011) (9)
- Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study (2022) (9)
- Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas (2018) (9)
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (9)
- Patient‐centredness in acute stroke care – a qualitative study from the perspectives of patients, relatives and staff (2020) (8)
- Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma (2020) (8)
- Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients. (2019) (8)
- Blood-brain barrier and brain edema. (2012) (8)
- FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (2013) (8)
- Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (8)
- Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas (2019) (8)
- Comment to: Parametric Response Map as an Imaging Biomarker to Distinguish Progression from Pseudoprogression in High-Grade Glioma: Pitfalls in Perfusion MRI in Brain Tumors (2010) (8)
- GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types (2021) (8)
- Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation (2019) (8)
- Drug Repositioning Meets Precision in Glioblastoma (2017) (8)
- Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. (2020) (7)
- Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients (2019) (7)
- Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. (2022) (7)
- Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial. (2022) (7)
- Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas. (2013) (7)
- Lumbar disk prolapse: response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. (2008) (7)
- Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 (2021) (7)
- Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies (2021) (7)
- Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. (2015) (7)
- Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? (2021) (7)
- Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy (2020) (7)
- Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. (2020) (7)
- AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas (2022) (7)
- MR-perfusion derived hemodynamic parametric response mapping of bevacizumab efficacy in recurrent glioblastoma (2016) (7)
- Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma (2016) (7)
- Impact of MGMT promoter methylation in glioblastoma of the elderly. (2011) (7)
- Radioresistance and transcriptional reprograming of invasive glioblastoma cells. (2021) (7)
- Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB). (2014) (7)
- Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study (2019) (7)
- Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma (2019) (7)
- A connectivity signature for glioblastoma (2021) (6)
- Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p (2018) (6)
- Normal mast cell numbers in the tissues of AhR‐deficient mice (2016) (6)
- A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma. (2015) (6)
- The aryl hydrocarbon receptor as a promoter of malignant glioma (2012) (6)
- Genetically Modified Cellular Therapies for Malignant Gliomas (2021) (6)
- Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma (2021) (6)
- Individualized blood pressure management during endovascular treatment of acute ischemic stroke under procedural sedation (INDIVIDUATE) – An explorative randomized controlled trial (2021) (6)
- One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma (2007) (6)
- Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy (2021) (6)
- Continuous-Time Deep Glioma Growth Models (2021) (6)
- HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA (2013) (5)
- PD1 and PD-L1 expression in glioblastoma. (2014) (5)
- Role of TGF-beta in oncogenesis. (2001) (5)
- Anaplastic gliomas: an emerging entity. (2011) (5)
- Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²). (2016) (5)
- Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. (2018) (5)
- CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. (2002) (5)
- Magnetization transfer ratio: a quantitative imaging biomarker for 5q spinal muscular atrophy (2020) (5)
- Glioblastoma: what's ischemia got to do with it? (2006) (5)
- Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study. (2010) (5)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. (2013) (5)
- EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma (2016) (5)
- CLIN-ONGOING CLINICAL TRIALS (2012) (5)
- 136 Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial (2015) (5)
- ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION (2019) (5)
- Brain Tumor Networks in Diffuse Glioma (2022) (5)
- Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study (2022) (5)
- T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas (2021) (5)
- DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis (2022) (5)
- AI-based decision support improves reproducibility of tumor response assessment in neuro-oncology: an international multi-reader study. (2022) (5)
- Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice (2007) (4)
- Time-dependent parameter of perfusion imaging as independent predictor of clinical outcome in symptomatic carotid artery stenosis (2016) (4)
- Oncolytic virotherapy: Potentially a game-changing tumor treatment. (2021) (4)
- Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. (2022) (4)
- MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors (2022) (4)
- DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment (2022) (4)
- PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) (2019) (4)
- Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation (2022) (4)
- Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial. (2020) (4)
- Guidelines on the Management of Low-grade Gliomas: EANO Task Force Report (2012) (4)
- Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma (2013) (4)
- BI-32RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY (2014) (4)
- Evidence-based management of adult patients with diffuse glioma - Authors' reply. (2017) (4)
- Primary CNS lymphoma after CLIPPERS: a case series (2021) (4)
- Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo. (2016) (4)
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (4)
- BI-22CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) (2014) (4)
- O6.02ANALYSIS OF PD1 AND PD-L1 EXPRESSION IN GLIOBLASTOMA (2014) (4)
- Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. (2017) (4)
- Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion (2021) (4)
- Tregs in gliomas - the jury is still out. (2015) (4)
- IB-02ROLE OF TUMOR INFILTRATING LYMPHOCYTES AND PDL1 EXPRESSION IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM): COMPARATIVE ANALYSIS. (2014) (4)
- VXM01 phase I study in patients with progressive glioblastoma: Final results. (2018) (4)
- Anendogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- 1H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy (2021) (3)
- “Nanomania” ante portas of neurooncology? (2011) (3)
- Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes. (2019) (3)
- Abstract LB-382: Inhibition of CD95 signalling by APG-101 enhances efficacy of radiotherapy (RT) and reduces RT-induced tumor satellite formation (2011) (3)
- Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients (2020) (3)
- OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas (2018) (3)
- Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2022) (3)
- CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE) (2020) (3)
- Emergency intubation during thrombectomy for acute ischemic stroke in patients under primary procedural sedation (2021) (3)
- Abstract 464: Methylation of a single CpG site in the CD95-ligand promoter is a biomarker predicting the response to therapy with APG101 in glioblastoma (2016) (3)
- Erbitux® (Cetuximab) Plus Temozolomide as Radiochemotherapy for Primary Glioblastoma (GERT): Interim Results of a Phase I/II Study (2008) (3)
- Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients (2021) (3)
- Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients (2017) (3)
- Outcome after Radiotherapy for Vestibular Schwannomas (VS)—Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy (2022) (3)
- Highlights in Central Nervous System Tumors. (2016) (3)
- 26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma (2015) (3)
- MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial. (2012) (3)
- Automated detection and quantification of brain metastases on clinical MRI data using artificial neural networks (2022) (3)
- Influence of expression of EGFR and PTEN on outcome in patients with primary glioblastoma treated with standard radiochemotherapy and cetuximab: Interim analysis from the GERT-Protocol. (2016) (3)
- Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. (2014) (3)
- “But it's a nice compromise” – Qualitative multi‐centre study of barriers and facilitators to acute telestroke cooperation in a regional stroke network (2021) (3)
- Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2): A follow‐up study (2022) (3)
- AAMP is a binding partner of costimulatory human B7-H3 (2022) (3)
- ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL (2016) (3)
- Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years (2005) (3)
- Epigenetic profiling reveals a subset of pediatric-type glioneuronal tumors characterized by oncogenic gene fusions involving several targetable kinases (2022) (2)
- One week on/one week off regimen of temozolomide for recurrent glioblastoma: A phase II study. (2004) (2)
- AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM]). (2014) (2)
- 1OROLE OF PDL1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES (TILS) IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM) (2014) (2)
- Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study (2021) (2)
- Validation of Prognostic Significance of IDH1 and MGMT in Patients with Glioblastoma: One Step Forward, and One Step Back? (2010) (2)
- PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL (2014) (2)
- Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial. (2019) (2)
- EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology (2012) (2)
- Incidence of brain metastases in patients treated with bevacizumab (2013) (2)
- CELL BIOLOGY AND SIGNALING (2010) (2)
- Not Yet Another Negative Trial–ReACTing on Recent Glioblastoma Trials (2020) (2)
- Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma (2022) (2)
- Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a follow-up study. (2022) (2)
- OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101) (2016) (2)
- Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma: Safety run-in results—NCT03750071. (2020) (2)
- Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio. (2016) (2)
- An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation (2017) (2)
- Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities (2016) (2)
- Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker. (2013) (2)
- Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes (2021) (2)
- Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial. (2015) (2)
- VXM01 phase I study in patients with resectable progression of a glioblastoma. (2017) (2)
- DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas (2022) (2)
- Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). (2019) (2)
- Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial (2008) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study. (2022) (2)
- How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors (2021) (2)
- Atnt-10Does Valproic Acid Improve Survival In Glioblastoma? A Meta-Analysis Of Randomized Trials In Newly Diagnosed Glioblastoma (2015) (2)
- Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma. (2014) (2)
- Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial ependymoma (2021) (1)
- Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma (2022) (1)
- NIMG-02. NON-INVASIVE DETECTION OF IDH MUTANT 1p19q NON-CODELETED GLIOMAS USING THE T2-FLAIR MISMATCH SIGN (2019) (1)
- Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio). (2016) (1)
- Molecular neuro-oncology: a forward-looking perspective. (2013) (1)
- GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION (2019) (1)
- CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA (2020) (1)
- Dietary tryptophan is required for CNS infiltration of encephalitogenic T cells (2014) (1)
- Glioma Invasion Confers Radioresistance (2012) (1)
- MEOX2 homeobox gene promotes growth of malignant gliomas (2021) (1)
- SYMPTOM MANAGEMENT/QUALITY OF LIFE (2013) (1)
- T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles (2023) (1)
- Steroid-Responsive Relapsing-Remitting Neutrophilic Encephalitis: A Case Report (2018) (1)
- What's New in Grade II and Grade III Gliomas? (2018) (1)
- Gadofluorine M enhanced MRI in experimental glioma: Superior and persistent intracellular tumor enhancement compared with conventional MRI (2012) (1)
- TMIC-27. GLUTAMATERGIC NEURON-GLIOMA SYNAPSES DRIVE BRAIN TUMOUR PROGRESSION (2019) (1)
- BSCI-11. Targeting PI3K/Akt/mTOR pathway to prevent melanoma brain metastasis (2021) (1)
- Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003) (2014) (1)
- OMICS AND PROGNSTIC MARKERS (2013) (1)
- Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling (2020) (1)
- Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours (2019) (1)
- PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON (2020) (1)
- FAST TRACK Modulation of TGF-b activity by latent TGF-b-binding protein 1 in human malignant glioma cells (2009) (1)
- mTORC 2:1 for chemotherapy sensitization in glioblastoma. (2011) (1)
- Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU) (2008) (1)
- ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (2017) (1)
- P08.19 Resistance towards the MDM2 inhibitor idasanutlin is mediated via the NFkB pathway and IGFBP1 upregulation in glioblastoma. (2017) (1)
- Reply to T.J. Kruser et al. (2016) (1)
- AT-17RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (2014) (1)
- OS07.1 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status. (2017) (1)
- Elderly people with glioblastoma - Authors' reply (2012) (1)
- Reply to F. Felix et al and M.F. Fay et al. (2016) (1)
- [Personalized therapy for gliomas]. (2015) (1)
- Improving outcome in newly diagnosed malignant glioma (2017) (1)
- [Immune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases]. (2013) (1)
- OS2.1 Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas. (2016) (1)
- ATIM-13. ASUNERCEPT PLUS RADIOTHERAPY IN RELAPSED GLIOBLASTOMA. UPDATE ON FIVE YEARS OVERALL SURVIVAL OF STUDY NCT01071837 AND DEVELOPMENT OF A POPULATION-PK - TUMOR GROWTH INHIBITION - SURVIVAL MODEL (2018) (1)
- Highlights of the inaugural ten - the launch of Neuro-Oncology Advances. (2019) (1)
- RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION (2020) (1)
- OS1.3 N-Myc downstream regulated gene 1 (NDRG1) influences the glioma tumor microenvironment (2016) (1)
- EXTH-28. NLGN4X TCR TRANSGENIC T CELLS TARGETING EXPERIMENTAL GLIOMAS (2021) (1)
- Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients (2022) (1)
- Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types (2022) (1)
- Active remodeling of capillary endothelium via cancer cell-derived MMP9 promotes metastatic brain colonization. (2023) (1)
- Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial (2021) (1)
- Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 (2022) (1)
- Assessment of Intratumoral Susceptibility Signals ( ITSS ) in Patients with newly diagnosed Glioblastoma using Quantitative Susceptibility Mapping ( QSM ) (2011) (1)
- P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma (2019) (1)
- P07.04 Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study (2021) (1)
- KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion (2021) (1)
- ANGI-07MR-PERFUSION DERIVED HEMODYNAMIC PARAMETRIC RESPONSE MAPPING OF BEVACIZUMAB EFFICACY IN RECURRENT GLIOBLASTOMA (2015) (1)
- NIMG-75. NECROSIS DURING TREATMENT IS ASSOCIATED WITH WORSE SURVIVAL IN RECURRENT GLIOBLASTOMA PATIENTS – POST HOC IMAGE ANALYSIS OF EORTC 26101 (2017) (1)
- QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING (2019) (1)
- CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658) (2022) (1)
- [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. (2010) (1)
- Glutamatergic synaptic input to glioma cells drives brain tumour progression (2019) (1)
- ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS (2018) (1)
- fundiInhibition of CD95/CD95L Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma (2018) (1)
- Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas (2022) (1)
- P08.31 A perivascular niche for progression and resistance in glioblastoma (2016) (1)
- P14.52 Differential methylation of a single CpG site in the CD95 ligand promoter affects gene activity and correlates with invasiveness of glioma cells (2019) (1)
- Lung toxicity of lomustine in the treatment of progressive gliomas (2022) (1)
- Quantitative magnetic resonance neurographic characterization of peripheral nerve involvement in manifest and pre‐ataxic spinocerebellar ataxia type 3 (2022) (1)
- Peripheral Nerve Involvement at First Diagnosis of Multiple Sclerosis (2022) (1)
- Patient Pathways During Acute in-Hospital Stroke Treatment: A Qualitative Multi-Method Study (2022) (1)
- Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (1)
- Faculty Opinions recommendation of An in vivo patient-derived model of endogenous IDH1-mutant glioma. (2012) (0)
- Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
- Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma (2019) (0)
- Reply to Lorenz et al.: Osteoprotegerin in the central nervous system (2004) (0)
- Means and methods for treating and / or preventing cancer natural ligand dependent AHR (2012) (0)
- Health-related quality of life (HRQoL) in AVAglio, a randomized, placebo (P)-controlled phase III study of bevacizumab (B), temozolomide (T) and radiotherapy (RI) in patients (pts) with newly diagnosed glioblastoma (GBM) (2013) (0)
- Improved risk stratification via integration of radiomics and dosiomics features in patients with recurrent high-grade glioma undergoing carbon ion radiotherapy (CIRT). (2021) (0)
- Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study. (2011) (0)
- Large-scale radiomic profiling of glioblastoma identifies an imaging signature for predicting and stratifying antiangiogenic treatment response (2016) (0)
- Large-scale radiomic profiling of newly diagnosed glioblastoma identifies an imaging predictor for survival stratification which outperforms established clinical and radiological risk models (2016) (0)
- Meningeosis neoplastica (2016) (0)
- CNSC-21. CHARACTERIZATION OF NEURON-TUMOR INTERACTIONS USING HUMAN CO-CULTURES (2022) (0)
- [Brain tumor immunotherapy-Possibilities and challenges of personalization]. (2021) (0)
- 23 INVITED Improving treatment for elderly patients with glioblastoma – is there a role for chemotherapy only? (2007) (0)
- IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING (2018) (0)
- Identification of an epigenetic biomarker predicting the response to therapy with APG101 in glioblastoma (2016) (0)
- 360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link? (2020) (0)
- Abstract 4238: DNA-methylation based epigenetic signatures predict and deconvolute somatic genomic alterations in gliomas (2019) (0)
- Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment. (2016) (0)
- [Structures of neurooncological science and care]. (2010) (0)
- SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) (2013) (0)
- OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas (2017) (0)
- Suppression of invasion-driving RGS 4 by radiation-enhanced mTOR inhibition optimizes antiangiogenesis (2017) (0)
- O6.09PROSTAGLANDIN E RECEPTOR-4 ACTIVATION REGULATES TRYPTOPHAN METABOLISM IN HUMAN MALIGNANT GLIOMAS (2014) (0)
- Impaired remission from autoimmune neuroinflammation upon T cell-specific knockout of the stress kinase GCN2 (2014) (0)
- CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY (2018) (0)
- O6.10GLIOMA CELL VEGFR-2 EXPRESSION IMPAIRS CHEMOTHERAPEUTIC AND ANTIANGIOGENIC TREATMENTS IN PTEN-DEFICIENT GLIOBLASTOMA (2014) (0)
- Temozolomide, irradiation and hypoxia promote homing of hematopoietic progenitor cells towards gliomas. (2006) (0)
- Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma (2016) (0)
- Selected Brain Tumor Related Abstracts from ASCO 2008 (Edited by Hong Lan) Summary Table (2008) (0)
- Abstract: Deep Probabilistic Modeling of Glioma Growth (2020) (0)
- Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry (2018) (0)
- INTEGRATED SYSTEMS AND TECHNOLOGIES 3206 Application of Raman Spectroscopy to Identify Microcalcifications and Underlying Breast Lesions at Stereotactic Core Needle Biopsy (2013) (0)
- P01.32 NDRG1 induced downregulation of CCL2 influences the migration of macrophages and impacts the tumor microenvironement (2017) (0)
- Erratum: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: A prospective single-arm monocentric phase-II study (RNOP-05) (Journal of Neuro-Oncology (2011) 104 (801-809) DOI:10.1007/s11060-011-0548-y) (2011) (0)
- Radiation Therapy for Desmoplastic Medulloblastoma-A Retrospective Analysis of Outcome and Prognostic Factors (2009) (0)
- Abstract 403: The role of HER2 in the brain metastatic cascade in breast cancer. (2013) (0)
- P08.54 Revisiting the,,go or grow” hypothesis in glioma in vivo (2016) (0)
- Online Database Featuring Author , Key Word and Full-Text Search Congress Report : ASCO 2011-The Neurooncology Perspective (2016) (0)
- Anaplastic pilocytic astrocytoma-an IDH-wildtype diffuse glioma characterized by a distinct DNA methylation profile and combined alterations in MAPK pathway genes, CDKN2A/B and ATRX (2017) (0)
- OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101 (2016) (0)
- OS2.6 Identification of IDH1R132H-specific T cell receptors from a humanized mouse model and from glioma patients treated with an IDH1R132H-specific peptide vaccine (2016) (0)
- RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY : EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS (2016) (0)
- P08.64 A NF-κB in vivo reporter system allows molecular insights into glioma progression and therapy response (2017) (0)
- 3745 NUCLEAR OVERHAUSER ENHANCEMENT ( NOE ) MEDIATED CHEMICAL EXCHANGE SATURATION TRANSFER ( CEST ) IMAGING AT 7 TESLA IN GLIOBLASTOMA PATIENTS (2013) (0)
- EORTC topics in neurooncology (2012) (0)
- Abstract 3797: Regulation and function of the mucin-like glycoprotein podoplanin in glioma. (2013) (0)
- BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA : RETROSPECTIVE ANALYSIS OF AVAglio (2016) (0)
- Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma : final results from AVAglio (2013) (0)
- In vivo and In vitro Cells Enhances Immunogenicity of Murine and Human Glioma Kinase Inhibitor , Inhibits Growth and Invasiveness and Receptor I β SD-208 , a Novel Transforming Growth Factor (2004) (0)
- CB-058. REGULATION OF CANCER PROMOTING TRYPTOPHAN CATABOLISM IN GLIOBLASTOMA BY THE GLUCOCORTICOID RECEPTOR (2013) (0)
- Tryptophan-2,3-dioxygenase in experimental autoimmune encephalomyelitis (2014) (0)
- RADT-34. ANALYSIS OF A METHYLATION CLASS-GUIDED RADIOTHERAPY IN MENINGIOMA PATIENTS - AND THE PROSPECTIVE PHASE II MARCIE TRIAL WITH CARBON-ION BOOST RADIOTHERAPY (2022) (0)
- Molecular Subtyping of Anaplastic Gliomas (2018) (0)
- PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS (2020) (0)
- A Vaccine Targeting Mutant IDH1 Induces Antitumor Immunity (S22.001) (2014) (0)
- Abstract 1803: Combining anti-Ang-2/VEGF-A therapy with radio- and chemotherapy in glioma (2017) (0)
- Radiogenomic rCBV-imaging visualizes the moleculare signature of IDH-mutant and wildtype gliomas (2016) (0)
- Un tumor palpebral raro (Fibro-condro-epitelioma) (0)
- P01.032 Associations of anticoagulant use with outcome in newly diagnosed glioblastoma (2018) (0)
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (0)
- Title Page / Table of Contents (2009) (0)
- OS2.2 Paracrine impairment of antitumor T cell immunity by IDH1-mutant gliomas (2016) (0)
- Retraction: Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma (Molecular & cellular proteomics : MCP (2018) 17 11 (2132-2145)) (2019) (0)
- Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
- Additional file 1: Figure S1. of Time-dependent parameter of perfusion imaging as independent predictor of clinical outcome in symptomatic carotid artery stenosis (2016) (0)
- Brain tumor-related edema (2007) (0)
- Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
- OS7.3 Impact of platelets and coagulation factors on the early steps of the brain metastatic cascade (2016) (0)
- Abstract 1308A: Novel antiinvasive and antiangiogenic mechanisms of mTOR inhibition in glioblastoma (2010) (0)
- Highlights from the literature (2014) (0)
- Faculty Opinions recommendation of Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. (2010) (0)
- P06.08 BRAINTuNE: Brain Tumor Neoepitope Evaluation for personalized glioma immunotherapy. (2017) (0)
- DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2016) (0)
- Avastin and Malignant Gliomas (2010) (0)
- Low-grade astrocytoma, anaplastic oligodendroglioma or astrocytoma, and glioblastoma: The clinical trial portfolio of the EORTC Brain Tumor and Radiation Oncology Groups for newly diagnosed patients. (2010) (0)
- QLIF-27. THE ADDED VALUE OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) AS A PROGNOSTIC INDICATOR OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOMA PATIENTS: A META-ANALYSIS BASED ON INDIVIDUAL PATIENT DATA FROM RANDOMIZED CONTROLLED TRIALS (2017) (0)
- Cancer Therapy : Clinical A Phase II , Randomized , Study of Weekly APG 101 þ Reirradiation versus Reirradiation in Progressive Glioblastoma (2014) (0)
- Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma (2023) (0)
- ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA (2016) (0)
- MOLECULAR GENETIC DETERMINANTS OF LONG-TERM SURVIVAL WITH GLIOBLASTOMA (2014) (0)
- Faculty Opinions recommendation of TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. (2011) (0)
- Shaping the glioma immune microenvironment through tryptophan (2012) (0)
- Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma (2015) (0)
- Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas (2020) (0)
- Eynde Depletion Tryptophan Catabolism in Cancer : Beyond IDO and Tryptophan (2012) (0)
- Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey. (2022) (0)
- Abstract 2487: Distinct venous brain vessels provide structures for T lymphocyte recruitment to brain tumors in mouse models of intracranial melanoma (2022) (0)
- Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N{superscript 2}M{superscript 2}). (2016) (0)
- Faculty Opinions recommendation of Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. (2010) (0)
- BIOM-39. ESTABLISHMENT OF A CONNECTIVITY SIGNATURE FOR GLIOMAS (2020) (0)
- Conventional and emerging treatments of astrocytomas and oligodendrogliomas. (2022) (0)
- P04.69 Differential microglia - glioma cell interaction during tumor progression (2018) (0)
- Author and Subject Index (2002) (0)
- P01.042 Symptom clusters in newly diagnosed glioma patients: which clusters are associated with functioning and global health status? (2018) (0)
- QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS? (2018) (0)
- Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study (2022) (0)
- Relaxation-compensated amide proton transfer (APT) MRI is a predictor of survival and progression in high-grade glioma patients (2019) (0)
- JS08.6.A A connectivity signature for glioblastoma (2022) (0)
- BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK? (2020) (0)
- MEOX2 homeobox gene promotes growth of malignant gliomas. (2022) (0)
- Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy (2018) (0)
- Dynamic Glucose Enhanced MRI at Ultra-High Field in Glioblastoma Patients (2016) (0)
- T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells (2022) (0)
- SP-0532: Molecular biomarkers in glioma: Prognostic or predictive? (2014) (0)
- 641 Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study (2022) (0)
- Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions (2023) (0)
- ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL (2018) (0)
- OS6.4 Molecular classification of meningiomas across all histological subtypes and grades (2016) (0)
- OS3.5 Dynamic insights into the cellular heterogeneity of malignant gliomas (2018) (0)
- Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival. (2023) (0)
- A NF-kB in vivo reporter system allows molecular insights into brain tumor progression and therapy response (2017) (0)
- PATH-27. MGMT PROMOTER STATUS IN IDH1/2 MUTANT ANAPLASTIC ASTROCYTOMA PATIENTS ASSESSED BY DNA METHYLATION PROFILING AND QMS-PCR: A REPORT FROM THE EORTC BRAIN TUMOR GROUP (2021) (0)
- P11.07 LAPTM5 functions as a tumor suppressor via CD40 - NFêB pathway inhibition and represents a potential biomarker for temozolomide sensitivity in CD40 proficient glioblastoma (2019) (0)
- P11.29 Development of ex vivo models for deeper insights into the biology and therapeutic targeting of tumor microtube networks in gliomas (2019) (0)
- P02.03 Multiple sclerosis and gliomas - a coincidence? (2016) (0)
- P141. Neuralgic amyotrophy associated with Hepatitis E infection – A case report (2015) (0)
- Potential of Relaxation-Weighted 23 Na-MRI for Brain Tumor Characterization (2011) (0)
- SDS2 CHALLENGES IN TREATMENT OF GLIOBLASTOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES (2019) (0)
- Chemotherapy for intracranial ependymoma in adults (2016) (0)
- IMMU-04. UNVEILING THE TUMOR-METABOLOME-IMMUNITY AXIS OF GLIOMA (2021) (0)
- P54 Irradiation-enhanced mammalian target of rapamycin (mTOR)-targeted glioblastoma therapy with CCI-779 (temsirolimus) (2009) (0)
- Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials. (2023) (0)
- MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE (2018) (0)
- Diagnostic value of gadolinium contrast administration for spinal cord magnetic resonance imaging in multiple sclerosis patients and correlative markers of lesion enhancement (2021) (0)
- NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION (2017) (0)
- QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING (2019) (0)
- Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature (2023) (0)
- Author Correction: Federated learning enables big data for rare cancer boundary detection (2023) (0)
- Abstract LB-A01: Molecular subgroup analysis of a randomized trial (EORTC 26082-22081) testing temsirolimus and radiation therapy versus chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma without methylation of the MGMT gene promoter (2015) (0)
- P04.52 Spontaneous intratumoral T cell responses against glioblastoma-associated antigens (2018) (0)
- HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. (2022) (0)
- PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE (2021) (0)
- EXTH-07. AN ANTISENSE OLIGONUCLEOTIDE AGAINST TUMOR MICROTUBES IN GLIOBLASTOMA AS A NEW THERAPEUTIC OPTION TO IMPROVE TUMOR SPECIFIC THERAPY (2022) (0)
- CNSC-33. TRANSCRIPTOMIC NEURON-TUMOR INTERACTION MAPPING OF EXTRACRANIAL TUMORS AND BRAIN METASTASES (2022) (0)
- DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development (2019) (0)
- Dynamic Glucose Enhanced MRI: A prospective study in healthy volunteers and glioblastoma patients (2017) (0)
- OLIG2 Influences Cell Proliferation and Differentiation Through Direct Effects on Glioma-Relevant Receptor Tyrosine Kinases (2016) (0)
- Nuclear Overhauser Enhancement Imaging of Glioblastoma Patients at 7 Tesla : Region Specific Correlation with Diffusion Weighted MRI (2014) (0)
- PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED (2021) (0)
- Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (0)
- Images of a 49 year-old man with a glioblastoma with an oligodendroglial component after radiochemotherapy. (2013) (0)
- The European Perspective Regarding Avastin and Malignant Gliomas (2010) (0)
- Letters to the Editor Systemic Effects of Local Tumor Ablation: Oncogenesis and Antitumor Induced Immunity (2016) (0)
- DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma (2022) (0)
- P02.08 Visualizing tumor cell - lymphocyte interactions in the brain metastatic cascade using in vivo two photon microscopy (2018) (0)
- P12.12.A Resolving the cellular architecture of infiltration zones in glioblastoma (2022) (0)
- PATH-46. COMPUTATIONAL HISTOPATHOLOGY INFORMED RAPID TARGETED NANOPORE SEQUENCING ENABLES AFFORDABLE NEXT DAY REPORTING OF COMPREHENSIVE MOLECULAR MARKERS FOR CNS TUMOUR DIAGNOSTICS (2022) (0)
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (0)
- UV irradiation-mediated systemic immune suppression through AHR signalling (2014) (0)
- 642 EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 EOGBM1–18/ROSALIE study (2022) (0)
- Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors (2014) (0)
- Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma (2015) (0)
- Suppression of Th1 differentiation by tryptophan supplementation in vivo (2017) (0)
- IMMU-26. VISUALIZING TUMOR CELL - LYMPHOCYTE INTERACTIONS IN THE BRAIN METASTATIC CASCADE USING IN VIVO TWO PHOTON MICROSCOPY (2018) (0)
- Cancer neuroscience: State of the field, emerging directions (2023) (0)
- In situ proximity ligation assay to evaluate presentation of a mutated CD4 epitope in human glioma tissue (2014) (0)
- P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling (2018) (0)
- Progression Patterns in Non-Contrast-Enhancing Gliomas Support Brain Tumor Responsiveness to Surgical Lesions (2022) (0)
- Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period (2021) (0)
- CNSC-30. IN VIVO DYNAMICS OF ASTROCYTE-GLIOBLASTOMA TUMOR NETWORKS (2022) (0)
- OS7.2 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making (2019) (0)
- OS3.1 Differential impact of Ang-2, VEGF-A and dual Ang-2/VEGF-A blocking on the efficacy of radio- and chemotherapy in a glioblastoma model (2016) (0)
- Amide proton transfer (APT) MRI is a predictor of survival and progression in high-grade glioma patients (2019) (0)
- P06.06 A mutation-specific vaccine for Histone-3 K27M-mutated gliomas. (2017) (0)
- OS7.1 Identification and characterization of brain metastasis initiating cells (2016) (0)
- Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas (2019) (0)
- Highlights from the literature (2013) (0)
- P13.01 Neuronal activity drives distinct invasion modes of glioma cells (2021) (0)
- Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial (2022) (0)
- P04.04 Optimizing dasatinib for glioblastoma treatment (2021) (0)
- P10.02 Combined methods of a micropump system and a chronic cranial window allows tumor observation with multi photon laser scanning microscopy under continuous treatment (2021) (0)
- P04.34 Low-dose irradiation increases recruitment and effector function of tumor-specific T cells in experimental gliomas (2018) (0)
- IN THE SPOTLIGHT Understanding and Targeting Alkylator Resistance in Glioblastoma (2014) (0)
- NIMG-48. TLR7/8-AGONIST-LOADED NANOPARTICLES REPROGRAM TUMOR-ASSOCIATED MYELOID CELLS FOR EFFECTIVE IMMUNOTHERAPY OF EXPERIMENTAL GLIOMA AND MRI-BASED TREATMENT MONITORING (2021) (0)
- Distribution of GOPC:ROS1 and other ROS1 fusions in glioma types (2021) (0)
- OS1.6 Tumor Microtubes contribute to resistance against surgical lesions, and chemotherapy in malignant glioma. (2016) (0)
- NIMG-41. NON-INVASIVE TRACKING OF T-CELL RECRUITMENT TO THE TUMOR MICROENVIRONMENT IN A MURINE GLIOMA MODEL BY HIGH FIELD CELLULAR MRI (2022) (0)
- P02.13 Before requiring a cure: towards preventing the outgrowth of brain metastases (2018) (0)
- Spatial probabilistic mapping of metabolite ensembles in mass spectrometry imaging (2021) (0)
- The Battle Between Amino Acid PET and Functional MRI: Precision of Tumor Delineation Examined by Glioma Progression Pattern After Radiation Therapy (2014) (0)
- Erratum to: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05) (2011) (0)
- Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling (2023) (0)
- CBIO-20. HIGH LEVELS OF TERT CONFER SENSITIVITY TO THE DNA HYPOMETHYLATING AGENT DECITABINE (DAC) IN GLIOMAS (2021) (0)
- DDIS-17. MULTI-LEVEL DRUG DEVELOPMENT PIPELINE FOR THE DISCOVERY OF TUMOR MICROTUBE TARGETING DRUGS (2018) (0)
- P04.27 Texture feature analysis to predict overall survival in recurrent glioblastoma treated in the DIRECTOR trial (2017) (0)
- Online Database Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2018) (0)
- Brain metastases: pathobiology and emerging targeted therapies Matthias PreusserDavid CapperAysegul Ilhan-MutluAnna Sophie Berghoff • Peter BirnerRupert BartschChristine MarosiChristoph Zielinski • Minesh P. MehtaFrank WinklerWolfgang WickAndreas von Deimling (2012) (0)
- Abstract 4736: N-myc downstream regulated gene 1: A novel mediator of hypoxia-driven chemoresistance in glioblastoma (2012) (0)
- NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS. (2017) (0)
- CSIG-18. CALCIUM COMMUNICATION IN GLIOMA: CRUCIAL PACEMAKER CELLS GOVERN TUMOR PROGRESSION (2020) (0)
- NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101 (2017) (0)
- P09.09 Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas (2016) (0)
- Preclinical and clinical applications of enzastaurin in the treatment of malignant gliomas (2007) (0)
- Targeted therapies in patients with newly diagnosed glioblastoma—A systematic meta‐analysis of randomized clinical trials (2023) (0)
- QLIF-12. HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091) (2017) (0)
- P01.140 An H3.3K27M long peptide vaccine induces expansion of specific CD4 and CD8 T cell clones in a patient with progressive H3.3K27M-mutant midline glioma (2018) (0)
- TMIC-18. ROLE OF MICROGLIA IN THE EARLY STEPS OF THE BRAIN METASTATIC CASCADE (2016) (0)
- Images of two patients who were treated with bevacizumab after completion of radiochemotherapy. (2013) (0)
- Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071. (2019) (0)
- OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM) (2019) (0)
- [Treatment of brain tumor patients: hyperthermia, hyperbaric oxygenation, electric fields or nanoparticles]. (2012) (0)
- ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. (2015) (0)
- Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2016) (0)
- OS2.4 Expression and relevance of tumoral and stromal MHC class II in gliomas (2016) (0)
- 117 INVITED Treatment options for glioblastoma failing standard first-line treatment (2007) (0)
- OS2.3 A mutation-specific vaccination approach for Histon H3.3 K27M-mutated gliomas (2016) (0)
- OS09.9 Identification of IDH1R132H-specific T cell receptors from glioma patients and from MHC-humanized mice (2017) (0)
- Glioma tropism of haematopoietic progenitor cells is mediated by CXCL12 (2005) (0)
- Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee (2020) (0)
- Neurocognitive Function (NCF) Substudy and Mini-Mental State Examination (MMSE) Results from the Randomized, Placebo-Controlled Phase III AVAglio Trial of Bevacizumab (BEV) Added to Radiotherapy (RT) and Temozolomide (TMZ) for Newly Diagnosed Glioblastoma (S22.002) (2014) (0)
- Abstract 3916: Differential roles of microglia and macrophages for glioma progression. (2013) (0)
- Radiological progression types following anti-angiogenic therapy predict survival in recurrent glioblastoma patients (2013) (0)
- CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
- Kills p53 Mutant and p53 Wild-type Glioma Cells in Synergy with Irradiation and CD95 Ligand 1 (2001) (0)
- Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup. (2019) (0)
- OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial (2018) (0)
- Highlights from the literature (1958) (0)
- Temozolomide Involves Caspase 3 Activity and Cleavage of Prevention of Irradiation-induced Glioma Cell Invasion by (2013) (0)
- Molecular analysis of meningioma increases prognostic power: A methylation-based classification and grading system (2018) (0)
- Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2. (2018) (0)
- IMMU-41. HIGH-THROUGHPUT RETRIEVAL OF THERAPEUTIC T CELL RECEPTORS FROM GLIOMA (2020) (0)
- Optimizing the use of alkylators in neuro-oncology (2011) (0)
- Abstract PR15: The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling (2019) (0)
- Sections of MR images of the glioblastoma presented in Figure 2. (2013) (0)
- tumor infiltrating lymphocytes in glioblastoma Running title : PD-L 1 expression in glioblastoma (2017) (0)
- DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas (2020) (0)
- Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial (2020) (0)
- ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2018) (0)
- GE-30OLIGOASTROCYTOMA DOES NOT EXIST: IN-SITU MOLECULAR GENETICS FAVORS CLASSIFICATION AS EITHER OLIGODENDROGLIOMA OR ASTROCYTOMA (2014) (0)
- neuroRAD 2019 (2019) (0)
- P04.04 Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion phenotype of T cells (2016) (0)
- ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL (2018) (0)
- NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS) (2022) (0)
- NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS (2017) (0)
- Irradiation and non-lethal hypoxia promote attraction of hematopoietic stem cells towards glioma cells by HIF1-mediated induction of CXCL12 (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wolfgang Wick?
Wolfgang Wick is affiliated with the following schools:
